German CDMO Rentschler expands biologics capacity with deal for Shire site

German CDMO, which is looking to grow its manufacturing network, is adding a site in the U.S. (Rentschler)

Shire started looking for a buyer for a small biologics manufacturing site in Massachusetts shortly after its buyout of Baxalta two years ago. It has finally made a deal.

German CDMO Rentschler Biopharma, which focuses on biologics development and manufacturing, says it has an agreement to buy the former Baxalta manufacturing site in Milford, Massachusetts. It will be Rentschler's first move into the U.S. 

The 100,000-square-foot facility has about 70 employees and Rentschler spokesperson said they have all be offered jobs. The family-owned Rentschler, which currently has about 850 workers, said it will continue to manufacture products for Shire after the deal closes. Terms of the deal were not disclosed.

Sponsored by Lubrizol Life Science

[Webinar] Cannabinoid Formulation - from Farm to Pharma

Wednesday, June 24, 2020 | 12pm ET / 9am PT

A handful of cannabinoid-based pharmaceutical products are on the market today, and an ever-growing number are in the global development pipeline. This webinar will explore key considerations in developing cannabinoid-based pharmaceutical products, including an overview of global pharmaceutical cannabinoid usage today, common challenges formulating with CBD and other cannabinoids, and more.

RELATED: German CDMO Rentschler expands biologics production capacity

Rentschler, which is looking to expand globally, two years ago added a new facility to its site in Laupheim, Germany, to expand its  capacity, saying it recognized the growing demand for biologics. It invested about  €24 million to add two 3,000-liter stainless steel bioreactors, more than doubling its capacity, and had plans to add 200 jobs.

The sale by Shire comes just after Japan’s Takeda announced it is buying the rare disease drug maker for $58 billion, a deal that is expected to result in more consolidation as Takeda looks for extra cash flow to pay for the deal.

Suggested Articles

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.

Alexion and Amgen reached a deal to put off a biosimilar challenger to Alexion's blockbuster rare disease med Soliris until March 2025.

A top adviser for the Trump administration is calling on Congress to push for more manufacturing in Puerto Rico.